About Us

About Us

OGV Biotec LLC was established in 2024 aiming to build a new veterinary vaccine production facility. Manufacturing at this facility is based on the latest cGMP standards, as well as specific requirements and compliance requirements of ISO & FDA. The primary goal is to produce high-quality veterinary vaccines Using the highest technology and the latest technical equipment.

OGV Biotech is committed to comprehensive production management using state-of-the-art, fully automated production systems to ensure a cleanand sterile environment.

Quality control is the cornerstone of the production process at OGV Biotech. These controls adhere to the European Pharmacopoeia regulations and Good ManufacturingPractices (cGMP), as well as ISO and FDA standards. This includes analysis of all incoming raw materials, inprocess controls, final product testing before release, and specific microbiological monitoring procedures to control any bacterial load.

Furthermore, all manufactured products are tested by specialists to verify their safety and efficacy.

To nurture the animal world by advancing Veterinary Vaccines for animals.

To be the most trusted and respected veterinary vaccine company in the region, and to contribute to shaping the future of animal health through our innovation, customer focus, and purposeful research and development efforts.

OGV Biotech is committed to achieving production management using highly advanced, fully automated systems to ensure comprehensive environmental cleanliness and sterility.

Quality control is the most important aspect of OGV Biotech's production process. These controls are subject to the European Pharmacopoeia and Good Manufacturing Practices (cGMP) regulations, in addition to compliance with ISO and FDA standards.

These include the analysis of all incoming raw materials, in-process control procedures, final inspections before product placement on the market, and specific microbiological control procedures to contain any bacterial load. Specialists also test the potency of all manufactured products to verify their safety and efficacy.Production is carried out in Class 100 sterile environments, and all production areas are equipped with laminar flowsystems. These systems are essential to meet the microbiological and quality requirements of production environments and processe.

Why Oman ?

The Sultanate of Oman enjoys a strategic location that connects East and West, connecting markets in Europe and Asia. Its location, adjacent to the Arabian Gulf and the Strait of Hormuz, allows it access to the world's most important shipping lanes, providing easy access to the Gulf states, Africa, and the Indian subcontinent. Oman is also an economically, politically, and socially stable country in the Middle East and North Africa region.

In addition, the Sultanate offers a modern framework for laws and regulations in the trade and investment sector, openness to global free trade markets, and the availability of ownership rights.

2 Billion Doses/ Year

The factory is set to achieve an impressive annual production capacity of 2 billion doses, ensuring:

• A vital supply of vaccines for poultry and livestock vaccines

• Addressing both local and export markets

• Adopting various technologies of vaccine production (Live attenuated & inactivated vaccines).

Image
Image

Rich Enviroment

Image

The Capital

Image

Our Care

Information

The content and presentation of the website https://ogv-biotec.com are protected by copyright and subject to German copyright law. Reproduction, use of individual texts or parts of texts, as well as images, requires our prior written consent. 

All Images are from FREEPIC or shot by OGV Team.